BB&T Securities’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

BB&T Securities’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$261K	Buy	5,545 +645	+13%	+$33.1K	﹤0.01%	1383
2019 Q2	$262K	Sell	4,900 -125	-2%	-$6.48K	﹤0.01%	1380
2019 Q1	$277K	Sell	5,025 -172	-3%	-$9.09K	﹤0.01%	1331
2018 Q4	$244K	Buy	5,197 +150	+3%	+$7.71K	﹤0.01%	1281
2018 Q3	$300K	Hold	5,047	–	–	﹤0.01%	1324
2018 Q2	$276K	Buy	5,047 +250	+5%	+$12.7K	﹤0.01%	1317
2018 Q1	$236K	Hold	4,797	–	–	﹤0.01%	1327
2017 Q4	$226K	Buy	+4,797	New	+$225K	﹤0.01%	1303

Other funds holding PBE

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

BB&T Securities's PBE Position: Q3 2019 in Review

BB&T Securities increased its Invesco Biotechnology & Genome ETF (PBE) stake by 13% in Q3 2019, buying an estimated $33.1K and bringing the position to 5,545 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #1383.

BB&T Securities first reported a position in PBE in Q4 2017 and has held it in 8 quarters since. The position peaked at $300K in Q3 2018. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

BB&T Securities held 5,545 shares of Invesco Biotechnology & Genome ETF worth $261K as of Q3 2019.
BB&T Securities bought 645 Invesco Biotechnology & Genome ETF shares in Q3 2019, an estimated $33.1K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1383 holding.
BB&T Securities first reported a position in Invesco Biotechnology & Genome ETF in Q4 2017 and has held it in 8 quarters since.
BB&T Securities's Invesco Biotechnology & Genome ETF position peaked at $300K in Q3 2018.
73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.